1.Dong Z, Liu Y, Scott KF, Levin L, Gaitonde K, Bracken RB, et al. Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancer. Carcinogenesis. 2010;31(11):1948–55.
2.Stangelberger A, Waldert M, Djavan B. Prostate cancer in elderly men. Reviews in urology. 2008;10(2):111–9.
3.Farran B, Dyson G, Craig D, Dombkowski A, Beebe-Dimmer JL, Powell IJ, et al. A study of circulating microRNAs identifies a new potential biomarker panel to distinguish aggressive prostate cancer. Carcinogenesis. 2018;39(4):556–61.
4.Hoang DT, Iczkowski KA, Kilari D, See W, Nevalainen MT. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles. Oncotarget. 2017;8(2):3724–45.
5.Saini S. PSA and beyond: alternative prostate cancer biomarkers. Cellular oncology (Dordrecht). 2016;39(2):97–106.
6.Trincado JL, Sebestyen E, Pages A, Eyras E. The prognostic potential of alternative transcript isoforms across human tumors. Genome medicine. 2016;8(1):85.
7.Adamopoulos PG, Mavrogiannis AV, Kontos CK, Scorilas A. Novel alternative splice variants of the human protein arginine methyltransferase 1 (PRMT1) gene, discovered using next-generation sequencing. Gene. 2019;699:135–44.
8.Qu LG, Wardan H, Davis ID, Iddawela M, Sluka P, Pezaro CJ. Circulating Estrogen Receptor Mutations and Splice Variants in Advanced Prostate Cancer. BJU international. 2019.
9.Albano F, Zagaria A, Anelli L, Coccaro N, Tota G, Brunetti C, et al. Absolute quantification of the pretreatment PML-RARA transcript defines the relapse risk in acute promyelocytic leukemia. Oncotarget. 2015;6(15):13269–77.
10.Zhu GQ, Zhou YJ, Qiu LX, Wang B, Yang Y, Liao WT, et al. Prognostic alternative mRNA splicing signature in hepatocellular carcinoma: a study based on large-scale sequencing data. Carcinogenesis. 2019.
11.Vitting-Seerup K, Sandelin A. The Landscape of Isoform Switches in Human Cancers. Molecular cancer research: MCR. 2017;15(9):1206–20.
12.Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ. The role of vitamin D in reducing cancer risk and progression. Nature reviews Cancer. 2014;14(5):342–57.
13.Petrou S, Mamais I, Lavranos G, I PT, Chrysostomou S. Effect of Vitamin D Supplementation in Prostate Cancer: A Systematic Review of Randomized Control Trials. International journal for vitamin and nutrition research Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung Journal international de vitaminologie et de nutrition. 2018;88(1–2):100–12.
14.Zhu Y, Chen P, Gao Y, Ta N, Zhang Y, Cai J, et al. MEG3 Activated by Vitamin D Inhibits Colorectal Cancer Cells Proliferation and Migration via Regulating Clusterin. EBioMedicine. 2018;30:148–57.
15.Trump DL, Aragon-Ching JB. Vitamin D in prostate cancer. Asian journal of andrology. 2018;20(3):244–52.
16.Chen J, Lobachev KS, Grindel BJ, Farach-Carson MC, Hyzy SL, El-Baradie KB, et al. Chaperone properties of pdia3 participate in rapid membrane actions of 1alpha,25-dihydroxyvitamin d3. Molecular endocrinology (Baltimore, Md). 2013;27(7):1065–77.
17.Cheng HS, Lee JXT, Wahli W, Tan NS. Exploiting vulnerabilities of cancer by targeting nuclear receptors of stromal cells in tumor microenvironment. Molecular cancer. 2019;18(1):51.
18.Campbell FC, Xu H, El-Tanani M, Crowe P, Bingham V. The yin and yang of vitamin D receptor (VDR) signaling in neoplastic progression: operational networks and tissue-specific growth control. Biochemical pharmacology. 2010;79(1):1–9.
19.Pressinotti NC, Klocker H, Schafer G, Luu VD, Ruschhaupt M, Kuner R, et al. Differential expression of apoptotic genes PDIA3 and MAP3K5 distinguishes between low- and high-risk prostate cancer. Molecular cancer. 2009;8:130.
20.Zhao G, Lu H, Li C. Proapoptotic activities of protein disulfide isomerase (PDI) and PDIA3 protein, a role of the Bcl–2 protein Bak. The Journal of biological chemistry. 2015;290(14):8949–63.
21.Takata H, Kudo M, Yamamoto T, Ueda J, Ishino K, Peng WX, et al. Increased expression of PDIA3 and its association with cancer cell proliferation and poor prognosis in hepatocellular carcinoma. Oncology letters. 2016;12(6):4896–904.
22.Ye Q, Fu P, Dou J, Wang N. Downregulation of PDIA3 inhibits proliferation and invasion of human acute myeloid leukemia cells. OncoTargets and therapy. 2018;11:2925–35
23.Uhlen M, Zhang C, Lee S, Sjostedt E, Fagerberg L, Bidkhori G, et al. A pathology atlas of the human cancer transcriptome. Science (New York, NY). 2017;357(6352).
24.UniProt Consortium T. UniProt: the universal protein knowledgebase. Nucleic acids research. 2018;46(5):2699.
25.Zhang Y. I-TASSER server for protein 3D structure prediction. BMC bioinformatics. 2008;9:40.
26.Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera—a visualization system for exploratory research and analysis. Journal of computational chemistry. 2004;25(13):1605–12.
27.Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nature methods. 2010;7(4):248–9.
28.Choi Y, Sims GE, Murphy S, Miller JR, Chan AP. Predicting the functional effect of amino acid substitutions and indels. PloS one. 2012;7(10):e46688.
29.Almagro Armenteros JJ, Sonderby CK, Sonderby SK, Nielsen H, Winther O. DeepLoc: prediction of protein subcellular localization using deep learning. Bioinformatics (Oxford, England). 2017;33(21):3387–95.
30.Zerbino DR, Achuthan P, Akanni W, Amode MR, Barrell D, Bhai J, et al. Ensembl 2018. Nucleic acids research. 2018;46(D1):D754-d61.
31.Hettinghouse A, Liu R, Liu CJ. Multifunctional molecule ERp57: From cancer to neurodegenerative diseases. Pharmacology & therapeutics. 2018;181:34–48.
32.Zhu Y, Cai L, Guo J, Chen N, Yi X, Zhao Y, et al. Depletion of Dicer promotes epithelial ovarian cancer progression by elevating PDIA3 expression. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2016;37(10):14009–23.
33.Trivedi R, Muller GA, Rathore MS, Mishra DP, Dihazi H. Anti-Leukemic Activity of Shikonin: Role of ERP57 in Shikonin Induced Apoptosis in Acute Myeloid Leukemia. Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology. 2016;39(2):604–16.
34.Brar GA, Weissman JS. Ribosome profiling reveals the what, when, where and how of protein synthesis. Nature reviews Molecular cell biology. 2015;16(11):651–64.
35.Kochetov AV. Alternative translation start sites and hidden coding potential of eukaryotic mRNAs. BioEssays: news and reviews in molecular, cellular and developmental biology. 2008;30(7):683–91.
36.Tournillon AS, Lopez I, Malbert-Colas L, Naski N, Olivares-Illana V, Fahraeus R. The alternative translated MDMX(p60) isoform regulates MDM2 activity. Cell cycle (Georgetown, Tex). 2015;14(3):449–58.
37.Climente-Gonzalez H, Porta-Pardo E, Godzik A, Eyras E. The Functional Impact of Alternative Splicing in Cancer. Cell reports. 2017;20(9):2215–26.